Mayne Pharma Group Gestion

Gestion contrôle des critères 1/4

Le PDG Mayne Pharma Group est Shawn O’Brien, nommé en Oct2022, a un mandat de 2.08 ans. La rémunération annuelle totale est A$ 2.06M, composée du salaire de 46.5% et des bonus 53.5%, y compris les actions et options de la société. détient directement 0.075% des actions de la société, d'une valeur de A$ 272.66K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 2.8 ans et 2.7 ans.

Informations clés

Shawn O’Brien

Directeur général

AU$2.1m

Rémunération totale

Pourcentage du salaire du PDG	46.5%
Durée du mandat du directeur général	2.1yrs
Propriété du PDG	0.07%
Durée moyenne d'occupation des postes de direction	2.8yrs
Durée moyenne du mandat des membres du conseil d'administration	2.7yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Shawn O’Brien a-t-elle évolué par rapport aux bénéfices de Mayne Pharma Group?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Jun 30 2024	AU$2m	AU$959k	-AU$169m
Mar 31 2024	n/a	n/a	-AU$221m
Dec 31 2023	n/a	n/a	-AU$274m
Sep 30 2023	n/a	n/a	-AU$296m
Jun 30 2023	AU$2m	AU$663k	-AU$317m

Rémunération vs marché: La rémunération totale de Shawn ($USD 1.34M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché Australian ($USD 708.27K ).

Rémunération et revenus: La rémunération de Shawn a augmenté alors que l'entreprise n'est pas rentable.

PDG

Shawn O’Brien (65 yo)

2.1yrs

Titularisation

AU$2,062,194

Compensation

Mr. Shawn Patrick O'Brien, B.Sc has been CEO, MD & Director at Mayne Pharma Group Limited since October 1, 2022. He serves as the Chief Commercial Advisor at Melanovus Oncology, Inc. Mr. O'Brien is a found...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Shawn O’Brien	CEO, MD & Director	2.1yrs	AU$2.06m	0.075% A$ 272.7k
Aaron Gray	Chief Financial Officer	2.3yrs	AU$1.31m	0.064% A$ 231.5k
Kimberly Parker	Executive VP & General Counsel	2.8yrs	pas de données	pas de données
Brant Schofield	Executive Vice President of Corporate Development	3.8yrs	AU$1.29m	pas de données
Erinn Nathaniel	Director of Global Human Resources	1.8yrs	pas de données	pas de données
Daniel Moore	Executive Vice President of Commercial	5.2yrs	pas de données	pas de données
Frank Casty	Executive VP & Global Chief Medical Officer	1.8yrs	pas de données	pas de données
Brenton Walter	Financial Controller	20.3yrs	pas de données	pas de données
Laura Loftus	Associate General Counsel & Company Secretary	4.7yrs	pas de données	pas de données

2.8yrs

Durée moyenne de l'emploi

Gestion expérimentée: L'équipe de direction de MYX est considérée comme expérimentée (ancienneté moyenne 2.8 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Shawn O’Brien	CEO, MD & Director	2.1yrs	AU$2.06m	0.075% A$ 272.7k
Frank Condella	Independent Non-Executive Chairman	6.5yrs	AU$305.40k	0.081% A$ 295.4k
Bruce Robinson	Independent Non-Executive Director	10.3yrs	AU$219.39k	0.039% A$ 142.2k
Patrick Blake	Independent Non-Executive Director	6.4yrs	AU$218.36k	0.027% A$ 99.0k
Ann Custin	Independent Non-Executive Director	2.7yrs	AU$235.16k	0.026% A$ 95.7k
Kathryn MacFarlane	Independent Non-Executive Director	2.8yrs	AU$215.84k	0.047% A$ 170.2k
Anne Lockwood	Independent Non Executive Director	less than a year	AU$117.49k	pas de données
David Petrie	Non-Executive Director	2.2yrs	AU$217.86k	pas de données

2.7yrs

Durée moyenne de l'emploi

62yo

Âge moyen

Conseil d'administration expérimenté: Le conseil d'administration de la MYX n'est pas considéré comme expérimenté ( 2.7 années d'ancienneté moyenne), ce qui suggère un nouveau conseil d'administration.

Mayne Pharma Group Gestion

Gestion contrôle des critères 1/4

Informations clés

Mises à jour récentes de la gestion

High number of new directors

Mayne Pharma Group Limited Approves Election of Anne Lockwood

Mayne Pharma Group Limited, Annual General Meeting, Nov 30, 2023

Independent Non-Executive Director recently bought AU$69k worth of stock

Mayne Pharma Group Limited Announces Retirement of Carolyn Myers from the Board At the End of July 2023

Independent Non-Executive Chairman recently bought AU$74k worth of stock

Recent updates

New major risk - Financial position

Full year 2024 earnings released: AU$2.12 loss per share (vs AU$3.86 loss in FY 2023)

No longer forecast to breakeven

New minor risk - Profitability

First half 2024 earnings released: AU$0.88 loss per share (vs AU$1.38 loss in 1H 2023)

Forecast to breakeven in 2026

Mayne Pharma Group Limited to Report Fiscal Year 2024 Results on Aug 23, 2024

Mayne Pharma Group Limited to Report First Half, 2024 Results on Feb 26, 2024

High number of new directors

Mayne Pharma Group Limited Approves Election of Anne Lockwood

Mayne Pharma Group Limited, Annual General Meeting, Nov 30, 2023

Independent Non-Executive Director recently bought AU$69k worth of stock

Full year 2023 earnings released: AU$3.86 loss per share (vs AU$3.20 loss in FY 2022)

New minor risk - Financial data availability

Mayne Pharma Group Limited to Report Fiscal Year 2023 Results on Aug 31, 2023

Mayne Pharma Group Limited Announces Retirement of Carolyn Myers from the Board At the End of July 2023

Independent Non-Executive Chairman recently bought AU$74k worth of stock

First half 2023 earnings released: AU$0.078 loss per share (vs AU$0.62 loss in 1H 2022)

Mayne Pharma Group Limited to Report First Half, 2023 Results on Feb 28, 2023

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces US Launch of Haloette, a Generic Version of Nuvaring

Mayne Pharma Group Limited (ASX:MYX) agreed to acquire Certain Assets of TherapeuticsMD, Inc. (NasdaqGS:TXMD).

High number of new directors

High number of new directors

Mayne Pharma Group Limited Declares Fully Franked Special Dividend, Payable on 27 January 2023

Catalent, Inc. (NYSE:CTLT) acquired Metrics, Inc. from Mayne Pharma Group Limited (ASX:MYX) for approximately $480 million.

Mayne Pharma Group Limited Announces Executive Changes Effective from 1 October 2022

Mayne Pharma Group Limited Announces Management Changes

Full year 2022 earnings released: AU$0.16 loss per share (vs AU$0.13 loss in FY 2021)

Scott Richards Plans to Retire as CEO of Mayne Pharma Group Limited

FDA Grants Approval to Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA of the Abbreviated New Drug Application (Anda) for Haloette

Mayne Pharma Group Limited and Mithra Pharmaceuticals, Sa Announces NEXTSTELLIS Oral Contraceptive Now Available in Australia

Mayne Pharma Group Limited Announces CFO Changes

Forecast breakeven date pushed back to 2024

First half 2022 earnings: EPS in line with expectations, revenues disappoint

Mayne Pharma Expands U.S Dermatology Portfolio

Insufficient new directors

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces Therapeutic Goods Administration Approval of NEXTSTELLIS® Oral Contraceptive

High number of new directors

Independent Non Executive Director Bruce Mathieson has left the company

Independent Chairman Roger Corbett has left the company

Independent Chairman Roger Corbett has left the company

U.S. Food and Drug Administration Approves Mayne Pharma LEXETTE for Adolescent Plaque Psoriasis

Forecast to breakeven in 2023

Independent Non-Executive Director recently bought AU$137k worth of stock

Full year 2021 earnings released: AU$0.13 loss per share (vs AU$0.061 loss in FY 2020)

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces Nextstellis Receives FDA Marketing Exclusivity and Phase Iii Data Published

Mayne Pharma Announces New Data Showing Treatment with Nextstellis® Investigational Combined Oral Contraceptive (Coc) Containing Drospirenone (Drsp) and Estetrol

Mayne Pharma Group Limited Launches Another Generic Oral Contraceptive

Revenue beats expectations

First half 2021 earnings released: AU$0.12 loss per share (vs AU$0.012 loss in 1H 2020)

Mayne Pharma Group Limited to Report Fiscal Year 2021 Results on Aug 27, 2021

New 90-day low: AU$0.32

Mayne Pharma Group Limited Launches MICROGESTIN 24 FE Tablets in the United States

New 90-day low: AU$0.32

New 90-day low: AU$0.32

Mayne Pharma Group Limited Provides Update on Women's Health Pipeline

Mayne Pharma Group Limited Appoints Peter Paltoglou as Chief Financial Officer

New 90-day low - AU$0.33

New 90-day low - AU$0.34

Full year earnings released

Mayne Pharma Group Limited to Report Fiscal Year 2020 Results on Aug 21, 2020

Mayne Pharma Group Limited(ASX:MYX) dropped from S&P/ASX 200 Index

Analyse de la rémunération des PDG

PDG

Titularisation

Compensation

Équipe de direction

Durée moyenne de l'emploi

Membres du conseil d'administration